IL20 and prostate carcinoma: We developed the anti-IL-20 monoclonal antibody (mAb) 7E, which was shown to neutralize the in vitro and in vivo activity of human and mouse IL-20, and showed that 7E treatment effectively alleviated inflammation and suppressed tumor growth in breast cancer and prostate cancer mouse models28,29.